ACRS Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of --. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat CEL-SCI Corp.'s return on equity of -266.61%.

Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 154.71%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 575.68%. Given that CEL-SCI Corp. has higher upside potential than Aclaris Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.619, which suggesting that the stock is 38.102% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are larger than CEL-SCI Corp. quarterly revenues of --. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 22.13x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of 16.24%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 154.71%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -33.84%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.619, which suggesting that the stock is 38.102% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 22.13x versus 1.25x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vivos Therapeutics, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of -79.61%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Vivos Therapeutics, Inc.'s return on equity of -315.1%.

Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 154.71%. On the other hand Vivos Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 155.81%. Given that Vivos Therapeutics, Inc. has higher upside potential than Aclaris Therapeutics, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.619, which suggesting that the stock is 38.102% less volatile than S&P 500. In comparison Vivos Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Vivos Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Vivos Therapeutics, Inc. quarterly revenues of $6.8M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Vivos Therapeutics, Inc.'s net income of -$5.4M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Vivos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 22.13x versus 1.07x for Vivos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xencor, Inc. has a net margin of -442.98% compared to Aclaris Therapeutics, Inc.'s net margin of -28.7%. Aclaris Therapeutics, Inc.'s return on equity of -103.93% beat Xencor, Inc.'s return on equity of -20.07%.

Aclaris Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 154.71%. On the other hand Xencor, Inc. has an analysts' consensus of $28.00 which suggests that it could grow by 54.36%. Given that Aclaris Therapeutics, Inc. has higher upside potential than Xencor, Inc., analysts believe Aclaris Therapeutics, Inc. is more attractive than Xencor, Inc..

Aclaris Therapeutics, Inc. has a beta of 0.619, which suggesting that the stock is 38.102% less volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.97%.

Aclaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aclaris Therapeutics, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.

Aclaris Therapeutics, Inc. quarterly revenues are $3.3M, which are smaller than Xencor, Inc. quarterly revenues of $21M. Aclaris Therapeutics, Inc.'s net income of -$14.6M is lower than Xencor, Inc.'s net income of -$6M. Notably, Aclaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aclaris Therapeutics, Inc. is 22.13x versus 8.93x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.